Public Workshop on the Trial Designs and Endpoints for Liver Disease Secondary to Nonalcoholic Fatty Liver Disease (NAFLD), September 5 - 6, 2013, FDA White Oak Campus, Bldg. 31 (Rm 1503), Silver Spring, MD 20993.
On September 5 – 6, 2013, FDA is conducting a public workshop on Trial Designs and Endpoints for Liver Disease Secondary to Nonalcoholic fatty liver disease (NAFLD). This workshop will provide a forum to discuss trial design, including endpoints for clinical trials in NAFLD, to promote efficient drug development in this area and thus improved treatments for patients. There are no approved treatments for NAFLD and its complications of nonalcoholic steatohepatitis (NASH) and liver fibrosis and cirrhosis.
This website will be updated as meeting materials are developed.